EGFR and non-small cell lung carcinoma: Single‐agent chemotherapy, including docetaxel 3, pemetrexed 4, and tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR‐TKI, including gefitinib 5, erlotinib 6, and icotinib 7), is approved for second‐line treatment in advanced NSCLC patients with a PS of 0–2.